Roche
Big PharmaSwiss pharma-diagnostics leader known for oncology and diagnostics integration. Key franchises include Tecentriq, Hemlibra, and Ocrevus. Pioneer in personalized medicine.
FDA Novel Drug Designations
(2016-2024)See 13 novel approvals →
Roche at a Glance
- Leading 21 drug targets across portfolio
- Fast trial execution (30 months median completion)
Upcoming FDA Decisions
Full Calendar →Roche's Key Drugs
Roche's core commercial portfolio centers on OCREVUS, OCREVUS ZUNOVO, VABYSMO, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
Relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease)
Multiple Sclerosis
Neovascular Age-Related Macular Degeneration
Hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
Non-Small Cell Lung Cancer
Roche News
All Roche news →- Oct 22, 2026 EarningsRoche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 ↗
- Oct 13, 2026 DealsRona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases ↗
- Oct 10, 2026 TrialsRoche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss ↗
- Oct 9, 2026 RegulatoryFDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer ↗
Roche's Recent FDA Approvals
Roche secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Roche's Therapeutic Areas
Roche's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 31 biologic and 9 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Roche's Top Competitors
Roche's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Eli Lilly, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Roche Pipeline Snapshot
Roche has 1051 active clinical programs from ClinicalTrials.gov — 340 Phase 3, 277 Phase 2 and 434 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 281/420 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (27)
Discontinued (0)
Company Info
- First Approval
- 1941-07-15
- Latest
- 2026-10-15
- Applications
- 119
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges